Addex sends allosteric modulator into Phase II for Parkinson's
This article was originally published in Scrip
Executive Summary
As expected, Addex Pharmaceuticals has started a Phase IIa trial to evaluate its lead internal programme, dipraglurant, in patients with Parkinson's disease levodopa-induced dyskinesia (PD-LID). The US and European study is supported in part by a grant from the Michael J. Fox Foundation for Parkinson Research. Results are due in the first half of 2012.